(5Z)-5-[(4-Oxo-4H-chromen-3-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one

Catalog No. :
ACGSNT823
CAS No. :
1446899-00-8
Molecular Formula :
C13H7NO3S2
Molecular Weight :
289.34

IUPAC Name:(Z)-5-((4-oxo-4H-chromen-3-yl)methylene)-2-thioxothiazolidin-4-one

(5Z)-5-[(4-Oxo-4H-chromen-3-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$324.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(5Z)-5-[(4-Oxo-4H-chromen-3-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
IUPAC Name(Z)-5-((4-oxo-4H-chromen-3-yl)methylene)-2-thioxothiazolidin-4-one
MDL No.MFCD05669845
Molecular FormulaC13H7NO3S2
Molecular Weight289.34
SMILESO=C1NC(S/C1=C\C2=COC3=C(C=CC=C3)C2=O)=S
InChI KeyVOQKYYMMDXMDIG-YHYXMXQVSA-N
Synonym(5Z)-5-[(4-oxo-4H-chromen-3-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one;4-Thiazolidinone, 5-[(4-oxo-4H-1-benzopyran-3-yl)methylene]-2-thioxo-, (5Z)-
CAS No.1446899-00-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACGSNT823 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACADET348 route compound structure diagram
    ACADET348141-84-4 In Stock
  2. Plus
  3. ACTYLZ067 route compound structure diagram
    ACTYLZ06717422-74-1 In Stock
  4. Then
  5. ACGSNT823 route product structure diagram
    ACGSNT8231446899-00-8
Inquiry

2. ACGSNT823 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFESO239 route compound structure diagram
    ACFESO23949619-82-1 In Stock
  4. Then
  5. ACGSNT823 route product structure diagram
    ACGSNT8231446899-00-8
Inquiry

Comments (0)